scholarly journals Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 291
Author(s):  
Miriam Marangon ◽  
Carlo Visco ◽  
Anna Maria Barbui ◽  
Annalisa Chiappella ◽  
Alberto Fabbri ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
Allogeneic Transplantation ◽  
Therapeutic Agents ◽  
New Drugs ◽  
Distinct Entity ◽  
T Cell Therapy ◽  
Car T Cell Therapy ◽  
Car T ◽  
Mantle Cell ◽  
Substantial Toxicity

MCL is an uncommon lymphoproliferative disorder that has been regarded as incurable since its identification as a distinct entity. Allogeneic transplantation for two decades has represented the only option capable of ensuring prolonged remissions and possibly cure. Despite its efficacy, its application has been limited by feasibility limitations and substantial toxicity, particularly in elderly patients. Nevertheless, the experience accumulated over time has been wide though often scattered among retrospective and small prospective studies. In this review, we aimed at critically revise and discuss available evidence on allogeneic transplantation in MCL, trying to put available evidence into the 2020 perspective, characterized by unprecedented development of novel promising therapeutic agents and regimens.

PO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma

2021 ◽  
Vol 161 ◽  
pp. S894-S895
Author(s):  
N. Figura ◽  
A. Sim ◽  
S. Dahiya ◽  
F. Lutfi ◽  
A. Rapoport ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Mantle Cell

scholarly journals Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease

2021 ◽  
Vol 19 (11.5) ◽  
pp. 1331-1333
Author(s):  
Mazyar Shadman
Keyword(s):  
T Cell ◽  
High Risk ◽  
Cell Therapy ◽  
Cell Lymphoma ◽  
Refractory Disease ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Mantle Cell

Mantle cell lymphoma remains incurable despite recent treatment advances, and most patients experience relapsed/refractory disease. BTK inhibitors are the preferred choice in the relapsed setting, especially in patients with early relapse. For patients with high-risk features such as TP53 mutation, early referral for CAR T-cell therapy should be considered, even in those with stable disease on a BTK inhibitor. Patients without high-risk features may be monitored and initiate CAR T-cell therapy after clinical disease progression. CAR T-cell therapy is an effective treatment with high rate of complete remissions. For patients who do not achieve a complete remission 3 months after CAR-T therapy, bridging therapy with chemotherapy or targeted therapy agents and referral for allogeneic transplant are recommended.

scholarly journals KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

2020 ◽  
Vol 382 (14) ◽  
pp. 1331-1342 ◽  
Author(s):  
Michael Wang ◽  
Javier Munoz ◽  
Andre Goy ◽  
Frederick L. Locke ◽  
Caron A. Jacobson ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Mantle Cell

scholarly journals Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

2020 ◽  
Vol 8 (2) ◽  
pp. e001114 ◽  
Author(s):  
Michael Wang ◽  
Preetesh Jain ◽  
T Linda Chi ◽  
Sheree E Chen ◽  
Amy Heimberger ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Cerebral Edema ◽  
Cell Lymphoma ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Mantle Cell

Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity.

Sign in / Sign up

Export Citation Format

Share Document